3月30日 - ** 制药商InsmedINSM.O股价盘前上涨3.8%，报150.82美元
** 摩根士丹利将该公司的评级从 "等权重 "上调至 "增持"；将目标价从166.00美元上调至212.00美元
** 新的目标价意味着该股较上次收盘价有约 48%的上涨空间
** 券商称，Insmed公司治疗慢性肺病支气管扩张症的新药Brinsupri正在以比预期更快的速度获得市场青睐。医生们对这种有助于减轻肺部炎症的药物越来越有信心，处方范围也在不断扩大。
** 摩根士丹利（Morgan Stanley）援引一份专有调查显示，85%的美国肺科医生已经开出了Brinsupri处方，预计到年底患者份额将增加近一倍。
** 截至上一交易日收盘，INSM股价累计下跌16.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.